Phase 2 Clinical Trial of GH001 in Bipolar II Disorder

Summary

This study is a multicenter, open-label, single-arm Phase 2 clinical trial. Approximately 15 participants with clinically diagnosed bipolar disorder (BD) type II and experiencing a current episode of depression will be included in this study. The participants will receive an individualized dosing regimen (IDR) with at least one and up to three doses of GH001 administered within a single day.

Timeline

Start

2023-04-06

Primary completion

2024-11-13

Completion

2024-12-05

Drugs

Indications